Newsroom
Sorted by: Latest
-
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the p...
-
Senegal Makes History as President Faye Opens First Youth Olympic Games on African Soil
DAKAR, Senegal--(BUSINESS WIRE)--Senegal makes history as President Faye opens first Youth Olympic Games on African soil...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
BeOne Medicines to Present at the Jefferies Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Me...
-
Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 26, 2026. The Company reported $3.5 billion in sales with total growth of 4.0%, and 3.1% internally in local currencies. GAAP earnings per share grew 26.2% versus the prior year. Non-GAAP earnings per share grew 13.0%, or 19.1% when excluding current-quarte...
-
Rockwell Medical Announces Transformational Global Hemodialysis Acquisition
WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical is acquiring Vantive’s HD concentrates, HD machines, water treatment systems, and related consumables and technical services business...
-
xMEMS Advances Edge AI with Solid-State Cooling and Audio at CES 2027
SANTA CLARA, Calif.--(BUSINESS WIRE)--xMEMS Labs showcases solid-state cooling and audio innovations at CES 2027, helping drive the next generation of Edge AI devices. Reserve a meeting....
-
Ropeg Wins ET Approvals Across Major Markets as European Patients Await Expanded Access
TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the United States, and China, widening treatment options for patients with the chronic disease. In Europe, however, the ET indication remains unapproved, underscoring the gap between clinical advances and patient access across global markets. Developed and manufactured by the Taiwan-based biopharmaceutical company P...
-
Bringg Introduces Performance AI, Intelligence That Works at the Decision Point, Not the Dashboard
CHICAGO--(BUSINESS WIRE)--Bringg introduces Performance AI, intelligence that works at the decision point, not the dashboard, for smarter last-mile decisions...